Datasets:
Dataset Preview
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code: DatasetGenerationError
Exception: CastError
Message: Couldn't cast
nctId: string
studyTitle: string
officialTitle: string
studyAcronym: string
overallStatus: string
studyType: string
phases: list<item: string>
child 0, item: string
primaryPurpose: string
studyAllocation: string
studyMasking: string
plannedEnrollment: int64
sponsorName: string
sponsorClass: string
sponsorOrganization: string
sponsorCollaborators: list<item: string>
child 0, item: string
studyConditions: list<item: string>
child 0, item: string
studyInterventions: list<item: string>
child 0, item: string
studyInterventionTypes: list<item: string>
child 0, item: string
primaryOutcomes: list<item: string>
child 0, item: string
patientSex: string
patientAgeMin: string
patientAgeMax: string
patientAgeGroups: list<item: string>
child 0, item: string
volunteersAccepted: bool
startDate: timestamp[s]
primaryCompletionDate: timestamp[s]
studyCompletionDate: timestamp[s]
postedDate: timestamp[s]
updatedDate: timestamp[s]
studyLocationCount: int64
studyCountries: list<item: string>
child 0, item: string
resultsPosted: bool
studyUrl: string
summary: string
scrapedAt: timestamp[s]
sourceQuery: string
_run_id: string
_dataset_id: string
fetchedAt: string
countryCode: string
vatNumber: string
name: string
address: string
isValid: bool
userError: string
requestDate: string
_complete: bool
_unbilled: bool
input: struct<vat: string, domain: string>
child 0, vat: string
child 1, domain: string
vatValid: bool
officialName: string
officialAddress: string
country: string
verificationSource: string
verifiedAt: string
viesStatus: string
website: string
title: string
description: string
socialLinks: struct<facebook: string, youtube: string, linkedin: string, instagram: string>
child 0, facebook: string
child 1, youtube: string
child 2, linkedin: string
child 3, instagram: string
emailsOnSite: list<item: null>
child 0, item: null
techHints: list<item: null>
child 0, item: null
confidence: double
to
{'nctId': Value('string'), 'studyTitle': Value('string'), 'officialTitle': Value('string'), 'studyAcronym': Value('string'), 'overallStatus': Value('string'), 'studyType': Value('string'), 'phases': List(Value('string')), 'primaryPurpose': Value('string'), 'studyAllocation': Value('string'), 'studyMasking': Value('string'), 'plannedEnrollment': Value('int64'), 'sponsorName': Value('string'), 'sponsorClass': Value('string'), 'sponsorOrganization': Value('string'), 'sponsorCollaborators': List(Value('string')), 'studyConditions': List(Value('string')), 'studyInterventions': List(Value('string')), 'studyInterventionTypes': List(Value('string')), 'primaryOutcomes': List(Value('string')), 'patientSex': Value('string'), 'patientAgeMin': Value('string'), 'patientAgeMax': Value('string'), 'patientAgeGroups': List(Value('string')), 'volunteersAccepted': Value('bool'), 'startDate': Value('timestamp[s]'), 'primaryCompletionDate': Value('timestamp[s]'), 'studyCompletionDate': Value('timestamp[s]'), 'postedDate': Value('timestamp[s]'), 'updatedDate': Value('timestamp[s]'), 'studyLocationCount': Value('int64'), 'studyCountries': List(Value('string')), 'resultsPosted': Value('bool'), 'studyUrl': Value('string'), 'summary': Value('string'), 'scrapedAt': Value('timestamp[s]'), 'sourceQuery': Value('string'), '_run_id': Value('string'), '_dataset_id': Value('string')}
because column names don't match
Traceback: Traceback (most recent call last):
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1816, in _prepare_split_single
for key, table in generator:
^^^^^^^^^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 613, in wrapped
for item in generator(*args, **kwargs):
~~~~~~~~~^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/packaged_modules/json/json.py", line 343, in _generate_tables
self._cast_table(pa_table, json_field_paths=json_field_paths),
~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/packaged_modules/json/json.py", line 132, in _cast_table
pa_table = table_cast(pa_table, self.info.features.arrow_schema)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2369, in table_cast
return cast_table_to_schema(table, schema)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2297, in cast_table_to_schema
raise CastError(
...<3 lines>...
)
datasets.table.CastError: Couldn't cast
nctId: string
studyTitle: string
officialTitle: string
studyAcronym: string
overallStatus: string
studyType: string
phases: list<item: string>
child 0, item: string
primaryPurpose: string
studyAllocation: string
studyMasking: string
plannedEnrollment: int64
sponsorName: string
sponsorClass: string
sponsorOrganization: string
sponsorCollaborators: list<item: string>
child 0, item: string
studyConditions: list<item: string>
child 0, item: string
studyInterventions: list<item: string>
child 0, item: string
studyInterventionTypes: list<item: string>
child 0, item: string
primaryOutcomes: list<item: string>
child 0, item: string
patientSex: string
patientAgeMin: string
patientAgeMax: string
patientAgeGroups: list<item: string>
child 0, item: string
volunteersAccepted: bool
startDate: timestamp[s]
primaryCompletionDate: timestamp[s]
studyCompletionDate: timestamp[s]
postedDate: timestamp[s]
updatedDate: timestamp[s]
studyLocationCount: int64
studyCountries: list<item: string>
child 0, item: string
resultsPosted: bool
studyUrl: string
summary: string
scrapedAt: timestamp[s]
sourceQuery: string
_run_id: string
_dataset_id: string
fetchedAt: string
countryCode: string
vatNumber: string
name: string
address: string
isValid: bool
userError: string
requestDate: string
_complete: bool
_unbilled: bool
input: struct<vat: string, domain: string>
child 0, vat: string
child 1, domain: string
vatValid: bool
officialName: string
officialAddress: string
country: string
verificationSource: string
verifiedAt: string
viesStatus: string
website: string
title: string
description: string
socialLinks: struct<facebook: string, youtube: string, linkedin: string, instagram: string>
child 0, facebook: string
child 1, youtube: string
child 2, linkedin: string
child 3, instagram: string
emailsOnSite: list<item: null>
child 0, item: null
techHints: list<item: null>
child 0, item: null
confidence: double
to
{'nctId': Value('string'), 'studyTitle': Value('string'), 'officialTitle': Value('string'), 'studyAcronym': Value('string'), 'overallStatus': Value('string'), 'studyType': Value('string'), 'phases': List(Value('string')), 'primaryPurpose': Value('string'), 'studyAllocation': Value('string'), 'studyMasking': Value('string'), 'plannedEnrollment': Value('int64'), 'sponsorName': Value('string'), 'sponsorClass': Value('string'), 'sponsorOrganization': Value('string'), 'sponsorCollaborators': List(Value('string')), 'studyConditions': List(Value('string')), 'studyInterventions': List(Value('string')), 'studyInterventionTypes': List(Value('string')), 'primaryOutcomes': List(Value('string')), 'patientSex': Value('string'), 'patientAgeMin': Value('string'), 'patientAgeMax': Value('string'), 'patientAgeGroups': List(Value('string')), 'volunteersAccepted': Value('bool'), 'startDate': Value('timestamp[s]'), 'primaryCompletionDate': Value('timestamp[s]'), 'studyCompletionDate': Value('timestamp[s]'), 'postedDate': Value('timestamp[s]'), 'updatedDate': Value('timestamp[s]'), 'studyLocationCount': Value('int64'), 'studyCountries': List(Value('string')), 'resultsPosted': Value('bool'), 'studyUrl': Value('string'), 'summary': Value('string'), 'scrapedAt': Value('timestamp[s]'), 'sourceQuery': Value('string'), '_run_id': Value('string'), '_dataset_id': Value('string')}
because column names don't match
The above exception was the direct cause of the following exception:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1369, in compute_config_parquet_and_info_response
parquet_operations, partial, estimated_dataset_info = stream_convert_to_parquet(
~~~~~~~~~~~~~~~~~~~~~~~~~^
builder, max_dataset_size_bytes=max_dataset_size_bytes
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
)
^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 948, in stream_convert_to_parquet
builder._prepare_split(split_generator=splits_generators[split], file_format="parquet")
~~~~~~~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1683, in _prepare_split
for job_id, done, content in self._prepare_split_single(
~~~~~~~~~~~~~~~~~~~~~~~~~~^
gen_kwargs=gen_kwargs, job_id=job_id, **_prepare_split_args
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
):
^
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1869, in _prepare_split_single
raise DatasetGenerationError("An error occurred while generating the dataset") from e
datasets.exceptions.DatasetGenerationError: An error occurred while generating the datasetNeed help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
nctId string | studyTitle string | officialTitle string | studyAcronym string | overallStatus string | studyType string | phases list | primaryPurpose string | studyAllocation string | studyMasking string | plannedEnrollment int64 | sponsorName string | sponsorClass string | sponsorOrganization string | sponsorCollaborators list | studyConditions list | studyInterventions list | studyInterventionTypes list | primaryOutcomes list | patientSex string | patientAgeMin string | patientAgeMax string | patientAgeGroups list | volunteersAccepted bool | startDate timestamp[s] | primaryCompletionDate timestamp[s] | studyCompletionDate timestamp[s] | postedDate timestamp[s] | updatedDate timestamp[s] | studyLocationCount int64 | studyCountries list | resultsPosted bool | studyUrl string | summary string | scrapedAt timestamp[s] | sourceQuery string | _run_id string | _dataset_id string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03945773 | Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors | A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors. | CaboPoint | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 127 | Ipsen | INDUSTRY | Ipsen | [] | [
"Locally Advanced or Metastatic Renal Cell Carcinoma"
] | [
"Cabozantinib"
] | [
"DRUG"
] | [
"Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2020-01-08T00:00:00 | 2023-05-11T00:00:00 | 2026-02-12T00:00:00 | 2019-05-10T00:00:00 | 2026-07-31T00:00:00 | 40 | [
"Austria",
"France",
"Germany",
"Netherlands",
"Spain",
"Switzerland",
"United Kingdom"
] | true | https://clinicaltrials.gov/study/NCT03945773 | The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or C... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04927494 | Cervical Cancer Prevention for Black Adults | Promoting Cervical Cancer Screening Among African American and Sub Saharan African Immigrants | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | SCREENING | NA | NONE | 288 | Adebola Adegboyega | OTHER | University of Kentucky | [
"National Cancer Institute (NCI)"
] | [
"Cervical Cancer"
] | [
"Health is Wealth: A Cervical Health Program"
] | [
"BEHAVIORAL"
] | [
"Number of Participants That Completed HPV Self-sampling",
"Change in Cervical Cancer Knowledge",
"Change in Human Papillomavirus (HPV) Knowledge",
"Change in Self-Efficacy in Completing Pap Test",
"Change in Perceived Barriers to Screening"
] | FEMALE | 30 Years | 65 Years | [
"ADULT",
"OLDER_ADULT"
] | true | 2023-01-01T00:00:00 | 2025-05-10T00:00:00 | 2025-06-20T00:00:00 | 2021-06-16T00:00:00 | 2026-07-31T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04927494 | The goal of this study is to develop and pilot test an intervention, entitled Health is Wealth: A Cervical Health Program, designed to promote screening and reduce perceived barriers to Cervical Cancer (CC) screening.
Aim 1: Examine general awareness and cultural factors (fatalism, religiosity/spirituality, temporal o... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04747249 | Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19 | Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19 | COVIPACT 2 | COMPLETED | INTERVENTIONAL | [
"NA"
] | TREATMENT | NA | NONE | 29 | Centre Francois Baclesse | OTHER | Centre Francois Baclesse | [] | [
"Solid Carcinoma",
"Post Traumatic Stress Disorder",
"Covid19"
] | [
"Psychological support"
] | [
"OTHER"
] | [
"Proportion of Patients With Improvement in Post-traumatic Stress Symptoms"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-06-18T00:00:00 | 2022-03-31T00:00:00 | 2022-09-05T00:00:00 | 2021-02-10T00:00:00 | 2026-07-31T00:00:00 | 1 | [
"France"
] | true | https://clinicaltrials.gov/study/NCT04747249 | In the context of the COVID-19 pandemic, concerns of the risk of infection may lead to fear, anxiety or psychological disorders that may become generalised and long-lasting, corresponding to post-traumatic stress disorder (PTSD). PTSD generally occurs in circumstances such as terrorist attacks, hostage-taking, bombings... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04205799 | Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure | A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure | CABOCOL-01 | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 57 | Centre Francois Baclesse | OTHER | Centre Francois Baclesse | [] | [
"Advanced/Metastatic Cervical Cancer"
] | [
"Cabozantinib"
] | [
"DRUG"
] | [
"Efficacy of Cabozantinib: Proportion of Patients With Disease Control Rate",
"Safety of Cabozantinib: Proportion of Patients With Clinical Gastro-intestinal (GI) Perforation/Fistula, GI-vaginal Fistula and Genito-urinary (GU) Fistula Events Grade ≥ 2 (NCI CTCAE v 5.0)"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2020-01-15T00:00:00 | 2023-01-15T00:00:00 | 2023-01-15T00:00:00 | 2019-12-19T00:00:00 | 2026-07-31T00:00:00 | 8 | [
"France"
] | true | https://clinicaltrials.gov/study/NCT04205799 | Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00400946 | 05-001: Treatment of Acute Lymphoblastic Leukemia in Children | Treatment of Acute Lymphoblastic Leukemia in Children | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | RANDOMIZED | NONE | 800 | Dana-Farber Cancer Institute | OTHER | Dana-Farber Cancer Institute | [
"National Cancer Institute (NCI)"
] | [
"Drug/Agent Toxicity by Tissue/Organ",
"Leukemia"
] | [
"asparaginase",
"cyclophosphamide",
"cytarabine",
"dexamethasone",
"dexrazoxane hydrochloride",
"doxorubicin hydrochloride",
"etoposide",
"leucovorin calcium",
"mercaptopurine",
"methotrexate",
"methylprednisolone",
"pegaspargase",
"prednisolone",
"therapeutic hydrocortisone",
"vincristi... | [
"DRUG",
"RADIATION"
] | [
"Asparaginase-Related Toxicity Rate"
] | ALL | 1 Year | 18 Years | [
"CHILD",
"ADULT"
] | false | 2005-04-01T00:00:00 | 2014-08-01T00:00:00 | 2019-06-01T00:00:00 | 2006-11-17T00:00:00 | 2026-07-30T00:00:00 | 8 | [
"United States",
"Canada"
] | true | https://clinicaltrials.gov/study/NCT00400946 | RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis. We have previously reported that patients with acute lymphoblastic leukemia in whom asparaginase treatm... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00183898 | Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 75 | University of Southern California | OTHER | University of Southern California | [
"Sanofi",
"Roche Global Development",
"Bristol-Myers Squibb"
] | [
"Gastric Cancer",
"Esophageal Cancer"
] | [
"oxaliplatin, capecitabine"
] | [
"DRUG"
] | [
"Rate of Progression-Free Survival (PFS) at Month 4"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2004-12-28T00:00:00 | 2013-02-04T00:00:00 | 2020-06-19T00:00:00 | 2005-09-16T00:00:00 | 2026-07-30T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT00183898 | This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after patients take the drugs capecitabine, oxaliplatin and cetuximab. Capecitabine (also called Xeloda) is a drug that has been approved by the Food and Drug Administration (... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01797523 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 62 | M.D. Anderson Cancer Center | OTHER | M.D. Anderson Cancer Center | [
"Novartis",
"National Cancer Institute (NCI)"
] | [
"Endometrial Cancer"
] | [
"Metformin",
"Letrozole",
"Everolimus"
] | [
"DRUG"
] | [
"Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1."
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2013-10-07T00:00:00 | 2026-02-04T00:00:00 | 2026-02-04T00:00:00 | 2013-02-22T00:00:00 | 2026-07-30T00:00:00 | 6 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01797523 | The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied.
Everolimus is designed to block a protein inside cancer cells that is involved in ca... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04761055 | Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer | Detection of Breast Lesions Utilizing iBreast Exam: A Comparison With Clinical Breast Exam | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | DIAGNOSTIC | NA | NONE | 300 | Memorial Sloan Kettering Cancer Center | OTHER | Memorial Sloan Kettering Cancer Center | [
"UE LifeSciences Inc.",
"Earlier.org"
] | [
"Breast Screening"
] | [
"Clinical Breast exam (CBE)",
"iBreastExam device",
"mammogram"
] | [
"DEVICE",
"DIAGNOSTIC_TEST",
"OTHER"
] | [
"Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations (CBE)by Estimating the Sensitivity of the Device Using Imaging Results",
"Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations by Estimating the Specificity of the Device Using Imaging Results"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-01-29T00:00:00 | 2025-08-19T00:00:00 | 2025-08-19T00:00:00 | 2021-02-18T00:00:00 | 2026-07-30T00:00:00 | 2 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04761055 | This study will test the iBreastExam device to find out whether it can detect a mass or lump in the breast as accurately as a routine breast cancer screening examination.
The iBreastExam is a handheld device that performs a painless electronic palpation (examination by touch) of the breast. The device is designed to d... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00038727 | Diabetes Prevention Program Outcomes Study | Diabetes Prevention Program Outcomes Study | DPPOS | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | PREVENTION | RANDOMIZED | NONE | 2,779 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | [
"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
"National Institute on Aging (NIA)",
"National Institute on Minority Health and Health Disparities (NIMHD)",
"National Heart, Lung, and Blood Institute (NHLBI)",
"National Cancer Institute (NCI)",
"National Eye Inst... | [
"Diabetes Mellitus",
"Cancer",
"CVD"
] | [
"DPPOS Group Lifestyle",
"Metformin",
"DPPOS Boost Lifestyle",
"Intensive Lifestyle Group Session"
] | [
"BEHAVIORAL",
"DRUG"
] | [
"Number of Participants With Diabetes.",
"Prevalence of Aggregate Microvascular Complication",
"Number of Participants With Total Cancer Except Non-melanoma Skin Cancer",
"Number of Participants With Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)"... | ALL | 25 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 1996-07-31T00:00:00 | 2020-02-28T00:00:00 | 2022-04-30T00:00:00 | 2002-06-05T00:00:00 | 2026-07-30T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT00038727 | The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstr... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02632409 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer | A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274) | CheckMate 274 | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | RANDOMIZED | TRIPLE | 709 | Bristol-Myers Squibb | INDUSTRY | Bristol-Myers Squibb | [
"Ono Pharmaceutical Co., Ltd."
] | [
"Various Advanced Cancer"
] | [
"Nivolumab",
"Placebo"
] | [
"BIOLOGICAL",
"OTHER"
] | [
"Disease Free Survival (DFS)",
"Disease Free Survival (DFS) in PD-L1 Expression ≥ 1% Population"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2016-03-22T00:00:00 | 2020-07-17T00:00:00 | 2026-05-19T00:00:00 | 2015-12-16T00:00:00 | 2026-07-30T00:00:00 | 188 | [
"United States",
"Argentina",
"Australia",
"Austria",
"Belgium",
"Brazil",
"Canada",
"Chile",
"China",
"Colombia",
"Denmark",
"France",
"Germany",
"Greece",
"Ireland",
"Israel",
"Italy",
"Japan",
"Mexico",
"Netherlands",
"Peru",
"Poland",
"Romania",
"Russia",
"South K... | true | https://clinicaltrials.gov/study/NCT02632409 | The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) | null | COMPLETED | INTERVENTIONAL | [
"PHASE4"
] | TREATMENT | RANDOMIZED | QUADRUPLE | 75 | Janssen Research & Development, LLC | INDUSTRY | Janssen Research & Development, LLC | [] | [
"Prostatic Neoplasms"
] | [
"Apalutamide",
"Placebo",
"Androgen-deprivation Therapy (ADT)"
] | [
"DRUG"
] | [
"Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria"
] | MALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-12-17T00:00:00 | 2023-06-01T00:00:00 | 2026-06-05T00:00:00 | 2019-09-30T00:00:00 | 2026-07-30T00:00:00 | 27 | [
"China"
] | true | https://clinicaltrials.gov/study/NCT04108208 | The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC). | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02654119 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 20 | University of Nebraska | OTHER | University of Nebraska | [
"National Cancer Institute (NCI)"
] | [
"HER2 Positive Breast Carcinoma",
"Stage I Breast Cancer AJCC v7",
"Stage IA Breast Cancer AJCC v7",
"Stage IB Breast Cancer AJCC v7",
"Stage II Breast Cancer AJCC v6 and v7",
"Stage IIA Breast Cancer AJCC v6 and v7",
"Stage IIB Breast Cancer AJCC v6 and v7"
] | [
"Cyclophosphamide",
"Laboratory Biomarker Analysis",
"Paclitaxel",
"Trastuzumab"
] | [
"BIOLOGICAL",
"DRUG",
"OTHER"
] | [
"Number of Participants With Neutropenia",
"Number of Participants With Paclitaxel-related Neuropathy",
"Number of Participants With Cardiotoxicity Grade 3/4 Cardiotoxicity, Graded According to the NCI CTCAE v4.03",
"Number of Participants With Grade 3/4 Nausea/Vomiting, Graded According to the NCI CTCAE v4.0... | FEMALE | 19 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2015-12-11T00:00:00 | 2025-12-08T00:00:00 | 2025-12-08T00:00:00 | 2016-01-13T00:00:00 | 2026-07-30T00:00:00 | 3 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02654119 | This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2/neu) positive breast cancer (confined to the breast or the breast and lymph nodes under the arm). Drugs ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01134575 | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 90 | M.D. Anderson Cancer Center | OTHER | M.D. Anderson Cancer Center | [
"Wyeth is now a wholly owned subsidiary of Pfizer"
] | [
"Acute Lymphoblastic Leukemia"
] | [
"CMC-544 (Inotuzumab Ozogamycin)",
"Rituximab"
] | [
"DRUG"
] | [
"Number of Patients With Response"
] | ALL | 16 Years | null | [
"CHILD",
"ADULT",
"OLDER_ADULT"
] | false | 2010-06-04T00:00:00 | 2018-04-18T00:00:00 | 2018-04-18T00:00:00 | 2010-06-02T00:00:00 | 2026-07-30T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01134575 | The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC) | null | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | NA | NONE | 96 | HUYABIO International, LLC. | INDUSTRY | HUYABIO International, LLC. | [] | [
"Melanoma",
"Renal Cell Carcinoma",
"Non-Small Cell Lung Cancer"
] | [
"HBI-8000 in combination with nivolumab"
] | [
"DRUG"
] | [
"Number of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2016-08-18T00:00:00 | 2023-12-12T00:00:00 | 2023-12-12T00:00:00 | 2016-03-24T00:00:00 | 2026-07-30T00:00:00 | 6 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02718066 | A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC).
The primary objective of this study is:
-To evaluate the safety and tolerability of HBI-8000 whe... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00458536 | Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF | Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF | null | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 36 | Beth Israel Deaconess Medical Center | OTHER | Beth Israel Deaconess Medical Center | [
"National Cancer Institute (NCI)",
"Dana-Farber Cancer Institute"
] | [
"Renal Cancer"
] | [
"Dendritic Cell Tumor Fusion Vaccine",
"Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)"
] | [
"BIOLOGICAL",
"DRUG"
] | [
"Number of Participants With Adverse Events Associated With Vaccination With Mature DC/Tumor Fusion and GM-CSF"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2004-10-01T00:00:00 | 2014-12-01T00:00:00 | 2023-07-01T00:00:00 | 2007-04-11T00:00:00 | 2026-07-29T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT00458536 | The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). Another purpose is to determine the type and severity of any side effects associated with this study vaccine... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01542021 | Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer | Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | TREATMENT | RANDOMIZED | NONE | 41 | Memorial Sloan Kettering Cancer Center | OTHER | Memorial Sloan Kettering Cancer Center | [
"Ferring Pharmaceuticals"
] | [
"Prostate Cancer",
"Prostatic Adenocarcinoma"
] | [
"degarelix injection",
"degarelix injection",
"androgen deprivation therapy"
] | [
"DRUG"
] | [
"Percent Change in Prostate Cancer Cell Proliferation (Ki-67 Levels)"
] | MALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2012-02-24T00:00:00 | 2024-09-30T00:00:00 | 2024-09-30T00:00:00 | 2012-03-01T00:00:00 | 2026-07-29T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01542021 | Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body.
Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has been no proven benefit with this approach.
The investigators do not expect the patient to be... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04763902 | Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer | Feasibility and Acceptability of Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer | TIMESPAN | COMPLETED | INTERVENTIONAL | [
"NA"
] | PREVENTION | RANDOMIZED | NONE | 39 | University of Utah | OTHER | University of Utah | [
"National Center for Advancing Translational Sciences (NCATS)"
] | [
"Endometrial Neoplasms"
] | [
"Time Restricted Eating (TRE) Schedule",
"Control Schedule"
] | [
"BEHAVIORAL"
] | [
"Proportion of Participants Referred That Were Consented and Enrolled",
"Attrition",
"Protocol Items Completed",
"Percentage of TRE-Adherent Days",
"Meals Delivered On Schedule",
"Study Visit Completion"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | true | 2021-02-18T00:00:00 | 2022-06-10T00:00:00 | 2022-09-30T00:00:00 | 2021-02-21T00:00:00 | 2026-07-29T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04763902 | The long-term goal of this study is to determine the efficacy of time restricted eating (TRE) for improving metabolic health and preventing endometrial cancer. The primary objective of the protocol is to conduct a 14-week two-arm randomized crossover trial of a dietary intervention to evaluate the feasibility, fidelity... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00505063 | Prospective Trial of Vaccine Responses in Childhood Cancer Survivors | Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 75 | Memorial Sloan Kettering Cancer Center | OTHER | Memorial Sloan Kettering Cancer Center | [] | [
"Childhood Cancer",
"Multiple Diseases"
] | [
"Immunization Schedule patients <7 years.",
"Immunization Schedule patients > or = to 7 years and <11 years of age",
"Immunization Schedule patients > or = to 11 years of age"
] | [
"BIOLOGICAL"
] | [
"Percentage of Participants With Protective Antibody Titers After Vaccination"
] | ALL | 2 Years | 18 Years | [
"CHILD",
"ADULT"
] | false | 2007-07-10T00:00:00 | 2025-06-11T00:00:00 | 2025-06-11T00:00:00 | 2007-07-20T00:00:00 | 2026-07-29T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT00505063 | This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standa... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03264131 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 16 | UNC Lineberger Comprehensive Cancer Center | OTHER | UNC Lineberger Comprehensive Cancer Center | [
"Seagen Inc."
] | [
"Lymphoma",
"Adult T-Cell Leukemia/Lymphoma",
"Lymphatic Diseases"
] | [
"Brentuximab Vedotin",
"CHEP"
] | [
"DRUG"
] | [
"Complete Response Rate After 2-6 Cycles of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP)"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-10-11T00:00:00 | 2023-12-15T00:00:00 | 2025-12-15T00:00:00 | 2017-08-28T00:00:00 | 2026-07-29T00:00:00 | 4 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03264131 | Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil, Iran, and Japan. Most cases of this disease in the United States occur along the East Coast due to emigration from the Caribbean islands. There is currently no standard treatment ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT06666556 | Bowel Preparation in Colonoscopy: Lactulose vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study. | Bowel Preparation in Colonoscopy: Lactulose vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study. | null | COMPLETED | INTERVENTIONAL | [
"PHASE4"
] | SCREENING | RANDOMIZED | SINGLE | 449 | Hospital Civil de Guadalajara | OTHER | Hospital Civil de Guadalajara | [
"Instituto Mexicano del Seguro Social"
] | [
"Colorectal Cancer Screening"
] | [
"Bowel preparation before colonoscopy",
"Bowel preparation before colonoscopy"
] | [
"COMBINATION_PRODUCT"
] | [
"Bowel Cleansing Was Assessed Using the Boston Bowel Preparation Scale (BBPS)."
] | ALL | 18 Years | 79 Years | [
"ADULT",
"OLDER_ADULT"
] | true | 2024-07-20T00:00:00 | 2025-07-31T00:00:00 | 2025-08-14T00:00:00 | 2024-10-30T00:00:00 | 2026-07-28T00:00:00 | 3 | [
"Mexico"
] | true | https://clinicaltrials.gov/study/NCT06666556 | The goal of this clinical trial it is to bowel the instestinal preparation with lactulose vs poliethylenglicol as better agent to have a quality colonoscopy and demostrate that lactulose is most efective, has a good tolerance and the patient would have a better satisfaction, so the question is:
wich is the eficancy of... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens | COMPANION-003 | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 49 | Compass Therapeutics | INDUSTRY | Compass Therapeutics | [] | [
"Metastatic Colorectal Cancer",
"Colon Cancer",
"Rectal Cancer"
] | [
"CTX-009"
] | [
"DRUG"
] | [
"Overall Response Rate"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2022-12-08T00:00:00 | 2025-05-15T00:00:00 | 2025-05-15T00:00:00 | 2022-08-24T00:00:00 | 2026-07-28T00:00:00 | 7 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT05513742 | This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.
A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03556384 | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) | An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 23 | Adam Burgoyne, MD, PhD | OTHER | University of California, San Diego | [] | [
"Gastrointestinal Stromal Tumors",
"Sdh",
"GIST",
"Cancer"
] | [
"Temozolomide"
] | [
"DRUG"
] | [
"Overall Response Rate"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-09-12T00:00:00 | 2023-06-22T00:00:00 | 2024-11-19T00:00:00 | 2018-06-14T00:00:00 | 2026-07-28T00:00:00 | 4 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03556384 | Funding Source - FDA OOPD
FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib. Although there are FDA-approved products for the treatment of advanced/metastatic GIST, these therapies are known to be ineffective in the SDH-mutant/deficient subtype and... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT06029517 | A Sugar-Sweetened Beverage Reduction Intervention for Native American Men | A Novel Sugar-Sweetened Beverage Reduction Intervention for Native American Men | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | PREVENTION | NON_RANDOMIZED | NONE | 48 | Roswell Park Cancer Institute | OTHER | Roswell Park Cancer Institute | [
"National Institute of Nursing Research (NINR)"
] | [
"Cardiovascular Disorder",
"Coronary Artery Disease",
"Diabetes Mellitus",
"Obesity-Related Malignant Neoplasm"
] | [
"Education Intervention",
"Observation of Indigenous SIPin Interventon",
"Discussion"
] | [
"OTHER"
] | [
"Change in SSB Intake for Men Affiliated With Native American Athletic Communities"
] | MALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | true | 2022-07-20T00:00:00 | 2025-09-15T00:00:00 | 2025-09-15T00:00:00 | 2023-09-08T00:00:00 | 2026-07-28T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT06029517 | This clinical trial develops and tests a culturally-appropriate educational program (Indigenous SIPin) for reducing sugar-sweetened beverage consumption in men affiliated with Native American athletics communities. Sugary drinks are drinks like pop, soda, and juice. Increased sugar consumption may lead to an increased ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC | null | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 40 | M.D. Anderson Cancer Center | OTHER | M.D. Anderson Cancer Center | [
"National Cancer Institute (NCI)"
] | [
"Recurrent Lung Non-Small Cell Carcinoma",
"Stage IV Lung Cancer AJCC v8",
"Stage IVA Lung Cancer AJCC v8",
"Stage IVB Lung Cancer AJCC v8"
] | [
"Durvalumab",
"Selumetinib",
"Tremelimumab"
] | [
"BIOLOGICAL",
"DRUG"
] | [
"Objective Response Rate (ORR) by RECIST v1.1"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-04-01T00:00:00 | 2025-10-30T00:00:00 | 2025-10-30T00:00:00 | 2018-07-10T00:00:00 | 2026-07-28T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03581487 | This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has come back. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system atta... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma | null | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | NA | NONE | 10 | Jennerex Biotherapeutics | INDUSTRY | SillaJen, Inc. | [] | [
"Melanoma"
] | [
"JX-594"
] | [
"BIOLOGICAL"
] | [
"Number of Participants With Objective Response in Injected Tumor(s)"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2007-02-01T00:00:00 | 2008-02-01T00:00:00 | 2009-12-01T00:00:00 | 2007-01-31T00:00:00 | 2026-07-27T00:00:00 | 3 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT00429312 | The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01339052 | Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma | A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 65 | L. Nicolas Gonzalez Castro, MD, PhD | OTHER | Dana-Farber Cancer Institute | [
"Brigham and Women's Hospital",
"Massachusetts General Hospital",
"Novartis Pharmaceuticals",
"M.D. Anderson Cancer Center",
"Memorial Sloan Kettering Cancer Center",
"University of California, San Francisco",
"University of California, Los Angeles",
"University of Utah"
] | [
"Glioblastoma"
] | [
"BKM120",
"Surgery"
] | [
"DRUG",
"PROCEDURE"
] | [
"Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1]",
"6-Month Progression-Free Survival (PFS6) [Cohort 2]",
"BKM120 Brain-to-Plasma Ratio at Time of Surgery [Cohort 1]",
"BKM120 Tumor Tissue Concentration at Time of Surgery [Cohort 1]",
"BKM120 Plasma Concentration a... | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2011-09-01T00:00:00 | 2016-10-01T00:00:00 | 2019-02-01T00:00:00 | 2011-04-20T00:00:00 | 2026-07-27T00:00:00 | 7 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01339052 | BKM120 is a newly discovered drug that has been used in other research studies. Information from those other research studies suggests that BKM120 may help to slow or stop the growth of malignant gliomas. The purpose of this study is to see how well BKM120 works in patients with malignant gliomas. Patients on this stud... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04975555 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 20 | University of Alabama at Birmingham | OTHER | University of Alabama at Birmingham | [
"Recordati Rare Diseases Inc"
] | [
"Cytokine Release Syndrome",
"ICANS",
"Lymphoma, Non-Hodgkin",
"Multiple Myeloma",
"Acute Lymphoblastic Leukemia"
] | [
"Siltuximab"
] | [
"DRUG"
] | [
"Participants With a Complete Response for Cytokine Release Syndrome (CRS)"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-11-15T00:00:00 | 2026-01-20T00:00:00 | 2026-01-20T00:00:00 | 2021-07-23T00:00:00 | 2026-07-27T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04975555 | This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | NA | NONE | 395 | Children's Oncology Group | NETWORK | Children's Oncology Group | [
"National Cancer Institute (NCI)"
] | [
"Stage III Kidney Wilms Tumor",
"Stage IV Kidney Wilms Tumor"
] | [
"3-Dimensional Conformal Radiation Therapy",
"Conventional Surgery",
"Cyclophosphamide",
"Dactinomycin",
"Doxorubicin Hydrochloride",
"Etoposide",
"Vincristine Sulfate Liposome"
] | [
"BIOLOGICAL",
"DRUG",
"PROCEDURE",
"RADIATION"
] | [
"Event Free Survival Probability",
"Event Free Survival (EFS) Probability",
"Event Free Survival Probability"
] | ALL | null | 29 Years | [
"CHILD",
"ADULT"
] | false | 2007-04-30T00:00:00 | 2016-06-30T00:00:00 | 2026-03-31T00:00:00 | 2006-09-21T00:00:00 | 2026-07-24T00:00:00 | 227 | [
"United States",
"Australia",
"Canada",
"Israel",
"New Zealand",
"Puerto Rico",
"Switzerland"
] | true | https://clinicaltrials.gov/study/NCT00379340 | This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping t... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 23 | Dana-Farber Cancer Institute | OTHER | Dana-Farber Cancer Institute | [
"Incyte Corporation"
] | [
"Inflammatory Breast Cancer (IBC)"
] | [
"Ruxolitinib",
"Paclitaxel",
"Doxorubicin",
"Cyclophosphamide"
] | [
"DRUG"
] | [
"Biologic Response To 7-Day Run-In Window Phase Treatment of Ruxolitinib Alone or Ruxolitinib Plus Paclitaxel"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-01-24T00:00:00 | 2022-12-31T00:00:00 | 2024-10-01T00:00:00 | 2016-08-23T00:00:00 | 2026-07-24T00:00:00 | 4 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02876302 | This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).
The Following drugs will be use in combination with Ruxolinitinib.
* Paclitaxel (also called Taxol)
* Doxorubicin also called Adriamycin
* Cyclophosphamide, also called Cytoxan | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03384134 | Treating Pain in Children With Cancer: Pain Buddy | Mobile Technology to Improve Pain and Symptoms in Children With Cancer | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | OTHER | RANDOMIZED | NONE | 407 | University of California, Irvine | OTHER | University of California, Irvine | [
"American Cancer Society, Inc.",
"National Cancer Institute (NCI)"
] | [
"Cancer"
] | [
"Pain Buddy"
] | [
"OTHER"
] | [
"Changes in Pain Severity Over Time"
] | ALL | 8 Years | 18 Years | [
"CHILD",
"ADULT"
] | false | 2019-08-01T00:00:00 | 2024-10-14T00:00:00 | 2025-06-30T00:00:00 | 2017-12-27T00:00:00 | 2026-07-24T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03384134 | The purpose of this study is to examine the feasibility of the ambulatory monitoring protocol, called Pain Buddy, in documenting children's pain, symptoms and quality of life while receiving outpatient chemotherapy. The long term goal of Pain Buddy is to help doctors, nurses, and parents get the information they need t... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02252887 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 45 | Memorial Sloan Kettering Cancer Center | OTHER | Memorial Sloan Kettering Cancer Center | [
"Genentech, Inc.",
"Hoffmann-La Roche",
"Hartford HealthCare"
] | [
"Metastatic HER2-Positive Breast Cancer"
] | [
"Gemcitabine",
"Trastuzumab",
"Pertuzumab"
] | [
"DRUG"
] | [
"Progression Free"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2015-01-12T00:00:00 | 2025-07-24T00:00:00 | 2025-07-24T00:00:00 | 2014-09-30T00:00:00 | 2026-07-24T00:00:00 | 5 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02252887 | The purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side effects and safety. A standard chemotherapy, gemcitabine, will be combined with 2 other drug... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03223753 | Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer | A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | PREVENTION | RANDOMIZED | NONE | 299 | Children's Oncology Group | NETWORK | Children's Oncology Group | [
"National Cancer Institute (NCI)"
] | [
"Carcinoma In Situ",
"Hematopoietic and Lymphatic System Neoplasm",
"Malignant Solid Neoplasm"
] | [
"Educational Intervention",
"Internet-Based Intervention",
"Internet-Based Intervention",
"Laboratory Biomarker Analysis",
"Medical Device Usage and Evaluation",
"Quality-of-Life Assessment",
"Questionnaire Administration"
] | [
"DEVICE",
"OTHER"
] | [
"Physiologic Cost Index (PCI)"
] | ALL | 8 Years | 16 Years | [
"CHILD"
] | false | 2017-11-29T00:00:00 | 2025-03-31T00:00:00 | 2026-03-31T00:00:00 | 2017-07-21T00:00:00 | 2026-07-24T00:00:00 | 118 | [
"United States",
"Canada"
] | true | https://clinicaltrials.gov/study/NCT03223753 | This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall healt... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03374332 | Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | null | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 11 | Brown University | OTHER | Brown University | [
"Rhode Island Hospital",
"The Miriam Hospital",
"Pfizer"
] | [
"Acute Myeloid Leukemia"
] | [
"Gemtuzumab Ozogamicin (GO)",
"Donor Leukocytes"
] | [
"DRUG",
"OTHER"
] | [
"Phase 1: Determine the RP2D or MTD of Nonengraftment Donor Leukocyte Infusions With Fractionated Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML Defined as Dose Level Without Dose Limiting Toxicities.",
"Response Rate"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-12-31T00:00:00 | 2023-09-26T00:00:00 | 2025-03-31T00:00:00 | 2017-12-15T00:00:00 | 2026-07-23T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03374332 | This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available. Researchers are studying whether the drug Gemtuzumab Ozogamicin, followed by an infusion of blood cells called leukocytes from a d... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer | AA NABPLAGEM | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 17 | HonorHealth Research Institute | OTHER | HonorHealth Research Institute | [
"Stand Up To Cancer",
"Cancer Research UK",
"Lustgarten Foundation",
"Translational Genomics Research Institute",
"Princeton University",
"Salk Institute for Biological Studies",
"Cold Spring Harbor Laboratory",
"Barts Cancer Institute",
"University of Arizona",
"Imaging Endpoints"
] | [
"Pancreatic Cancer",
"Pancreas Cancer",
"Pancreatic Adenocarcinoma Resectable",
"Pancreatic Ductal Adenocarcinoma",
"Pancreas Metastases"
] | [
"High Dose Ascorbic Acid 25 g/m^2",
"Nanoparticle Paclitaxel protein bound 125mg/m^2",
"Cisplatin 25mg/m^2",
"Gemcitabine 1000mg/m^2",
"High Dose Ascorbic Acid 37.5 g/m^2",
"High Dose Ascorbic Acid 56.25 g/m^2",
"High Dose Ascorbic Acid 75 g/m^2"
] | [
"DRUG"
] | [
"Total Dose Received [Identifying Recommended Maximum Tolerated Dose (MTD)]",
"Duration of Dose in Days [Identifying Recommended Maximum Tolerated Dose (MTD)]",
"Duration of Dose in Weeks [Identifying Recommended Maximum Tolerated Dose (MTD)]",
"Disease Control Rate (CR+PR+SD at 18 Weeks)",
"Best Overall Re... | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2017-12-15T00:00:00 | 2021-09-14T00:00:00 | 2023-09-06T00:00:00 | 2018-01-25T00:00:00 | 2026-07-23T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03410030 | The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02905578 | A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) | A Phase II Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer (PACMAN 2.1) | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | SINGLE | 40 | University of Iowa | OTHER | University of Iowa | [
"National Institutes of Health (NIH)",
"National Cancer Institute (NCI)",
"Holden Comprehensive Cancer Center",
"McGuff Pharmaceuticals, Inc."
] | [
"Pancreatic Neoplasms",
"Cancer of Pancreas",
"Cancer of the Pancreas",
"Neoplasms, Pancreatic",
"Pancreas Cancer",
"Pancreas Neoplasms",
"Adenocarcinoma"
] | [
"Gemcitabine",
"nab-paclitaxel",
"Pharmacological ascorbate"
] | [
"DRUG"
] | [
"Overall Survival"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-11-28T00:00:00 | 2024-08-26T00:00:00 | 2024-08-26T00:00:00 | 2016-09-19T00:00:00 | 2026-07-23T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02905578 | This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate in addition to the standard treatment). | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03836209 | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 181 | PrECOG, LLC. | OTHER | PrECOG, LLC. | [
"Astellas Pharma Inc"
] | [
"Acute Myeloid Leukemia"
] | [
"Gilteritinib",
"Midostaurin",
"Daunorubicin",
"Cytarabine"
] | [
"DRUG"
] | [
"FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction"
] | ALL | 18 Years | 70 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-12-06T00:00:00 | 2023-10-17T00:00:00 | 2026-06-30T00:00:00 | 2019-02-11T00:00:00 | 2026-07-23T00:00:00 | 44 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03836209 | Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03712878 | 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies | A 2 Step Approach to Matched Related Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies-5+5 Dosing | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | OTHER | Thomas Jefferson University | [] | [
"Hematopoietic and Lymphoid Cell Neoplasm"
] | [
"Total-Body Irradiation",
"Donor Lymphocyte Infusion",
"Cyclophosphamide",
"Allogeneic Hematopoietic Stem Cell Transplantation",
"Tacrolimus",
"Mycophenolate Mofetil"
] | [
"DRUG",
"PROCEDURE",
"RADIATION"
] | [
"Percentage of Participants With Donor T Cell Chimerism Values Greater Than or Equal to 98%"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-09-19T00:00:00 | 2025-03-19T00:00:00 | 2025-03-19T00:00:00 | 2018-10-19T00:00:00 | 2026-07-23T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03712878 | This phase II trial studies how well a 2-step approach to stem cell transplant works in treating patients with blood cancers. Giving chemotherapy and total body irradiation before a lymphocyte (white blood cell) and stem cell transplant helps stop the growth of cells in the bone marrow including normal blood-forming ce... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05736497 | Care Plans for Cancer Predisposition | Integration of Multimodal Cancer Predisposition Genetic Counseling Practices Within the Pediatric Oncology Setting: Digital Care Plans for Patients With CPS | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | SUPPORTIVE_CARE | NA | NONE | 177 | Children's Hospital of Philadelphia | OTHER | Children's Hospital of Philadelphia | [
"National Institutes of Health (NIH)",
"National Human Genome Research Institute (NHGRI)"
] | [
"Genetic Predisposition"
] | [
"Digital Care Plans"
] | [
"OTHER"
] | [
"Change in Knowledge Score"
] | ALL | 12 Years | null | [
"CHILD",
"ADULT",
"OLDER_ADULT"
] | false | 2023-08-25T00:00:00 | 2025-06-10T00:00:00 | 2025-06-10T00:00:00 | 2023-02-21T00:00:00 | 2026-07-23T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT05736497 | Develop and evaluate acceptability, feasibility, and preliminary efficacy of digital care plan and accompanying text message reminders for children and adolescents with a known Cancer Predisposition Syndromes (CPS). | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04281017 | Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients | Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients | null | COMPLETED | INTERVENTIONAL | [
"PHASE4"
] | SUPPORTIVE_CARE | RANDOMIZED | NONE | 22 | University of Florida | OTHER | University of Florida | [] | [
"Intraocular Pressure",
"Oncology"
] | [
"TIVA",
"Balanced anesthesia"
] | [
"DRUG"
] | [
"Quantify the Degree of Change in Intra Ocular Pressure in Female Patients Undergoing Robotic Procedures"
] | FEMALE | 18 Years | 99 Years | [
"ADULT",
"OLDER_ADULT"
] | true | 2020-11-10T00:00:00 | 2025-11-20T00:00:00 | 2026-02-20T00:00:00 | 2020-02-21T00:00:00 | 2026-07-23T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04281017 | Steep Trendelenburg positioning and insufflation of the abdominal cavity have shown to increase intra ocular pressure. Different anesthetic techniques can alter intra ocular pressure and a small pilot study showed decrease in Intraocular Pressure (IOP) in robotic case in steep Trendelenburg with IV anesthetics (TIVA).
... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04776447 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients | APOLO | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 38 | Fundación GECP | OTHER | Fundación GECP | [] | [
"Lung Diseases",
"Carcinoma, Non-Small-Cell Lung",
"Stage IIIA Non-small Cell Lung Cancer",
"Stage IIIB Non-small Cell Lung Cancer",
"Respiratory Tract Neoplasms",
"Carcinoma Bronchiogenic Stage III",
"Thoracic Neoplasms"
] | [
"Carboplatin",
"Placlitaxel",
"Atezolizumab"
] | [
"DRUG"
] | [
"To Assess the Efficacy of the Treatment in Terms of the Progression Free Survival (PFS) at 12 Months"
] | ALL | 18 Years | 75 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-06-16T00:00:00 | 2025-01-15T00:00:00 | 2025-07-31T00:00:00 | 2021-03-01T00:00:00 | 2026-07-22T00:00:00 | 22 | [
"Spain"
] | true | https://clinicaltrials.gov/study/NCT04776447 | Open-label, non-randomized, phase II multi-centre controlled clinical trial.
51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Sur... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00076310 | OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer | A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 50 | M.D. Anderson Cancer Center | OTHER | M.D. Anderson Cancer Center | [
"Genentech, Inc."
] | [
"Head and Neck Cancer"
] | [
"Docetaxel",
"OSI-774",
"Cisplatin"
] | [
"DRUG"
] | [
"Overall Response Assessment (Radiographic RECIST)"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2004-01-28T00:00:00 | 2025-05-01T00:00:00 | 2025-05-01T00:00:00 | 2004-01-21T00:00:00 | 2026-07-22T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT00076310 | The goal of this clinical research study is to learn if giving the new drug, Tarceva® (OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective in the treatment of metastatic or recurrent head and neck cancer. The safety of this treatment will also be studied. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05198934 | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | CodeBreak300 | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | RANDOMIZED | NONE | 160 | Amgen | INDUSTRY | Amgen | [] | [
"Colorectal Cancer (CRC)"
] | [
"Sotorasib",
"Panitumumab",
"Trifluridine and Tipiracil",
"Regorafenib"
] | [
"DRUG"
] | [
"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR"
] | ALL | 18 Years | 100 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2022-04-19T00:00:00 | 2025-07-16T00:00:00 | 2026-04-14T00:00:00 | 2022-01-20T00:00:00 | 2026-07-22T00:00:00 | 105 | [
"United States",
"Australia",
"France",
"Germany",
"Greece",
"Italy",
"Japan",
"Mexico",
"South Korea",
"Spain",
"Taiwan",
"United Kingdom"
] | true | https://clinicaltrials.gov/study/NCT05198934 | The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04645147 | Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults | Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350- Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection | null | COMPLETED | INTERVENTIONAL | [
"PHASE1"
] | OTHER | NON_RANDOMIZED | NONE | 83 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | National Institutes of Health Clinical Center (CC) | [] | [
"EBV",
"Epstein-Barr Virus Infection",
"Infectious Mononucleosis"
] | [
"EBV gp350-Ferritin Vaccine"
] | [
"BIOLOGICAL"
] | [
"Number of Participants With Solicited Local Adverse Events (AEs)",
"Number of Participants With Solicited Local Adverse Events (AEs) (by Severity)",
"Number of Participants With Solicited Systemic Adverse Events (AEs)",
"Number of Participants With Solicited Systemic Adverse Events (AEs) (by Grade)",
"Numb... | ALL | 18 Years | 29 Years | [
"ADULT"
] | false | 2022-03-29T00:00:00 | 2025-07-01T00:00:00 | 2026-04-01T00:00:00 | 2020-11-27T00:00:00 | 2026-07-22T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04645147 | Background:
Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Up to 1 in 10 people who get mono can have fatigue that lasts more than 6 months. One out of 100 people can have severe complications. EBV is also associated with several types of cancer. Researchers want to test an EBV vaccine.... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03796767 | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer (SOAR) | SOAR | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NON_RANDOMIZED | NONE | 20 | University of Utah | OTHER | University of Utah | [] | [
"Recurrent Prostate Carcinoma",
"Metastatic Malignant Neoplasm in the Bone",
"Metastatic Malignant Neoplasm in the Lymph Nodes",
"Oligometastasis",
"Prostate Adenocarcinoma",
"PSA Failure"
] | [
"Hypofractionated Radiation Therapy",
"Intensity-Modulated Radiation Therapy",
"Metastasectomy",
"Quality-of-Life Assessment",
"Questionnaire Administration",
"Stereotactic Body Radiation Therapy"
] | [
"OTHER",
"PROCEDURE",
"RADIATION"
] | [
"Prostate-specific Antigen (PSA) ≥ 50% 6 Months After Completion of All Treatment"
] | MALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-09-09T00:00:00 | 2024-02-13T00:00:00 | 2026-03-11T00:00:00 | 2019-01-08T00:00:00 | 2026-07-22T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03796767 | This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Surgical procedures, such as oligometastasectomy, may remove tumor ce... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04303780 | Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | RANDOMIZED | NONE | 345 | Amgen | INDUSTRY | Amgen | [] | [
"KRAS p, G12c Mutated /Advanced Metastatic NSCLC"
] | [
"AMG 510",
"Docetaxel"
] | [
"DRUG"
] | [
"Progression-free Survival (PFS)"
] | ALL | 18 Years | 100 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2020-06-04T00:00:00 | 2022-08-02T00:00:00 | 2026-06-24T00:00:00 | 2020-03-11T00:00:00 | 2026-07-22T00:00:00 | 274 | [
"United States",
"Australia",
"Belgium",
"Brazil",
"Canada",
"Denmark",
"Finland",
"France",
"Germany",
"Greece",
"Hungary",
"Italy",
"Japan",
"Netherlands",
"Poland",
"Portugal",
"Russia",
"South Korea",
"Spain",
"Sweden",
"Switzerland",
"Taiwan",
"United Kingdom"
] | true | https://clinicaltrials.gov/study/NCT04303780 | A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 88 | National Cancer Institute (NCI) | NIH | National Cancer Institute (NCI) | [] | [
"Recurrent Melanoma",
"Stage IIIA Cutaneous Melanoma AJCC v7",
"Stage IIIB Cutaneous Melanoma AJCC v7",
"Stage IIIC Cutaneous Melanoma AJCC v7",
"Stage IV Cutaneous Melanoma AJCC v6 and v7"
] | [
"Ipilimumab",
"Laboratory Biomarker Analysis",
"Recombinant Interferon Alfa-2b"
] | [
"BIOLOGICAL",
"OTHER"
] | [
"Progression-free Survival (PFS)"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2013-03-25T00:00:00 | 2017-08-08T00:00:00 | 2026-05-26T00:00:00 | 2012-10-17T00:00:00 | 2026-07-21T00:00:00 | 276 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01708941 | This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, may block tumor growth by targeting certain cells. Recombinant interfer... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03006848 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 19 | St. Jude Children's Research Hospital | OTHER | St. Jude Children's Research Hospital | [
"Pfizer",
"Gateway for Cancer Research"
] | [
"Osteosarcoma"
] | [
"Avelumab",
"Questionnaires"
] | [
"DRUG",
"OTHER"
] | [
"Response Rate",
"Progression-free Survival"
] | ALL | 12 Years | 49 Years | [
"CHILD",
"ADULT"
] | false | 2017-02-16T00:00:00 | 2020-03-18T00:00:00 | 2020-03-18T00:00:00 | 2016-12-30T00:00:00 | 2026-07-21T00:00:00 | 4 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03006848 | This clinical trial seeks to determine if avelumab will be effective in facilitating removal of all gross tumor in the event of a relapse of osteosarcoma in pediatric patients. Avelumab will be evaluated using dosing that has previously been determined in adult studies.
Primary Objectives:
* To estimate the response ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03048942 | Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | A Randomised Phase II Pilot Study of 3 Weekly Cabazitaxel Versus Weekly Paclitaxel Chemotherapy in the First Line Treatment of HER2 Negative Breast Cancer | CONCEPT | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 158 | University Hospitals Bristol and Weston NHS Foundation Trust | OTHER | University Hospitals Bristol and Weston NHS Foundation Trust | [] | [
"HER2 Negative Metastatic Breast Cancer"
] | [
"Cabazitaxel",
"Paclitaxel"
] | [
"DRUG"
] | [
"Progression Free Survival"
] | FEMALE | 18 Years | 99 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2014-12-18T00:00:00 | 2021-04-26T00:00:00 | 2025-03-19T00:00:00 | 2017-02-09T00:00:00 | 2026-07-21T00:00:00 | 13 | [
"United Kingdom"
] | true | https://clinicaltrials.gov/study/NCT03048942 | 90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to determine the difference in progression free survival between the 2 groups. If results at that stage suggest a potential benefit then... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04669197 | Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer | A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 19 | HonorHealth Research Institute | OTHER | HonorHealth Research Institute | [] | [
"Untreated Resectable Pancreatic Adenocarcinoma",
"Borderline Resectable Pancreatic Adenocarcinoma",
"Locally Advanced Pancreatic Adenocarcinoma"
] | [
"Paclitaxel protein bound",
"Gemcitabine",
"Cisplatin",
"Hydroxychloroquine"
] | [
"DRUG"
] | [
"CA 19-9 Normalization"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2020-12-01T00:00:00 | 2024-02-21T00:00:00 | 2025-07-31T00:00:00 | 2020-12-16T00:00:00 | 2026-07-21T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04669197 | To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02337829 | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | A Phase II Study Using ACP-196 (Acalabrutinib) in Patients With Relapsed/Refractory and Treatment-naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Antitumor Response. | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 48 | Acerta Pharma BV | INDUSTRY | Acerta Pharma BV | [
"National Institutes of Health (NIH)"
] | [
"Chronic Lymphocytic Leukemia",
"Small Lymphocytic Lymphoma"
] | [
"Acalabrutinib (Arm A)",
"Acalabrutinib (Arm B)"
] | [
"DRUG"
] | [
"Response Based on Overall Response Rate"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2015-01-12T00:00:00 | 2020-06-26T00:00:00 | 2025-10-31T00:00:00 | 2015-01-14T00:00:00 | 2026-07-21T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02337829 | This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04743934 | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer | RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer | RAD 2003 | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | QUADRUPLE | 44 | Andrew McDonald | OTHER | University of Alabama at Birmingham | [
"National Cancer Institute (NCI)"
] | [
"Prostate Adenocarcinoma"
] | [
"Flibanserin 100 MG",
"Placebo",
"Androgen deprivation therapy"
] | [
"DRUG"
] | [
"Number of Participants Who Reported Attempting Sexual Intercourse at Least 3 Times in the Prior Month"
] | MALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-07-02T00:00:00 | 2025-03-01T00:00:00 | 2026-03-01T00:00:00 | 2021-02-08T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04743934 | This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma. | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | RANDOMIZED | NONE | 863 | Merck Sharp & Dohme LLC | INDUSTRY | Merck Sharp & Dohme LLC | [
"Eisai Inc."
] | [
"Metastatic Esophageal Squamous Cell Carcinoma"
] | [
"Pembrolizumab",
"Lenvatinib",
"Cisplatin",
"5-FU",
"Oxaliplatin",
"Leucovorin",
"Levoleucovorin",
"Paclitaxel"
] | [
"BIOLOGICAL",
"DRUG"
] | [
"Part 1 (FP and TP Safety Run-in): Number of Participants With Dose Limiting Toxicities (DLTs)",
"Part 1 (FP and TP Safety Run-in): Number of Participants With Adverse Events (AEs)",
"Part 1 (FP and TP Safety Run-in): Number of Participants Who Discontinued Study Treatment Due to an AE",
"Part 2 (Main Study):... | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-07-28T00:00:00 | 2025-05-08T00:00:00 | 2026-05-20T00:00:00 | 2021-07-02T00:00:00 | 2026-07-20T00:00:00 | 198 | [
"United States",
"Argentina",
"Canada",
"Chile",
"China",
"Costa Rica",
"Denmark",
"France",
"Guatemala",
"Hong Kong",
"Hungary",
"Italy",
"Japan",
"Malaysia",
"Romania",
"Russia",
"Singapore",
"South Africa",
"South Korea",
"Spain",
"Taiwan",
"Thailand",
"Turkey (Türkiye... | true | https://clinicaltrials.gov/study/NCT04949256 | The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma.
The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherap... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04164979 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC) | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 34 | University of California, Irvine | OTHER | University of California, Irvine | [
"Exelixis"
] | [
"Gastric Adenocarcinoma",
"GastroEsophageal Cancer"
] | [
"Cabozantinib",
"Pembrolizumab"
] | [
"DRUG"
] | [
"Percentage of Participants With Progression-free Survival at 6 Months"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2020-02-04T00:00:00 | 2023-11-25T00:00:00 | 2025-09-16T00:00:00 | 2019-11-15T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04164979 | This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05775289 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | TRIPLE | 182 | Hoffmann-La Roche | INDUSTRY | Hoffmann-La Roche | [] | [
"Non-small Cell Lung Cancer"
] | [
"Tobemstomig",
"Pembrolizumab",
"Paclitaxel",
"Pemetrexed",
"Carboplatin"
] | [
"DRUG"
] | [
"Progression-Free Survival (PFS)",
"Objective Response Rate (ORR)"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2023-03-15T00:00:00 | 2024-06-20T00:00:00 | 2026-04-30T00:00:00 | 2023-03-20T00:00:00 | 2026-07-20T00:00:00 | 50 | [
"United States",
"Australia",
"Belgium",
"Brazil",
"France",
"Germany",
"Italy",
"Mexico",
"South Korea",
"Spain",
"Turkey (Türkiye)"
] | true | https://clinicaltrials.gov/study/NCT05775289 | The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metas... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04401267 | Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma | Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | SINGLE | 51 | St. Jude Children's Research Hospital | OTHER | St. Jude Children's Research Hospital | [
"National Cancer Institute (NCI)"
] | [
"Hypertension",
"Osteonecrosis",
"Osteonecrosis Due to Drug"
] | [
"Intensive Antihypertensive Therapy",
"Conventional Antihypertensive Therapy",
"Symptom Survey",
"Semi-structured interview"
] | [
"DRUG",
"OTHER"
] | [
"Extensive Radiographic Osteonecrosis"
] | ALL | 10 Years | null | [
"CHILD",
"ADULT",
"OLDER_ADULT"
] | false | 2020-10-15T00:00:00 | 2023-09-25T00:00:00 | 2025-10-07T00:00:00 | 2020-05-26T00:00:00 | 2026-07-20T00:00:00 | 2 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04401267 | This is a randomized unblinded Phase II clinical trial evaluating the impact of intensive antihypertensive control (targeted to the 50-75th percentile for age, sex, and height) compared to conventional antihypertensive control (targeted to the 90-95th percentile for age, sex, and height) on the incidence of radiographi... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01750567 | A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL | A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 37 | University of Michigan Rogel Cancer Center | OTHER | University of Michigan Rogel Cancer Center | [] | [
"Relapsed Chronic Lymphocytic Leukemia"
] | [
"Metformin"
] | [
"DRUG"
] | [
"Time to Treatment Failure"
] | ALL | 18 Years | 80 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2012-11-01T00:00:00 | 2025-02-28T00:00:00 | 2025-02-28T00:00:00 | 2012-12-17T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01750567 | Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication. More recently metformin has been shown to act against carcinomas by two mechanisms: 1) an indirect, insulin-dependent mechanism which sensitizes tissues to insulin, inhibits hepatic gluconeogenesis, and stimulates uptake ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT06098690 | Culturally Tailored HPV Psychoeducational Multimedia Intervention | Implementing Innovative and Strategic Approaches to Prevent and Mitigate the Deleterious Effects of HPV Across the Lifespan of Hispanics of Mexican Origin: Community Intervention | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | PREVENTION | RANDOMIZED | DOUBLE | 63 | University of Texas, El Paso | OTHER | University of Texas, El Paso | [
"National Institute on Minority Health and Health Disparities (NIMHD)"
] | [
"Health Knowledge, Attitudes, Practice",
"Vaccine-Preventable Diseases",
"Intention",
"Adherence, Patient"
] | [
"Culturally Tailored Multimedia Psychoeducational HPV Intervention",
"General HPV Multimedia Psychoeducational Control Group"
] | [
"BEHAVIORAL"
] | [
"Number of Participants With Human Papillomavirus (HPV) Vaccine Uptake After the Survey",
"Changes in Human Papillomavirus (HPV) Vaccination Intention Score"
] | ALL | 18 Years | 45 Years | [
"ADULT"
] | true | 2024-05-02T00:00:00 | 2024-08-28T00:00:00 | 2024-08-28T00:00:00 | 2023-10-24T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT06098690 | Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV). Our hypothesis is that adults who view culturally tailored multimedia stories encouraging HPV vaccination will re... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01302834 | Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer | Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | RANDOMIZED | NONE | 987 | Radiation Therapy Oncology Group | NETWORK | Radiation Therapy Oncology Group | [
"National Cancer Institute (NCI)",
"NRG Oncology"
] | [
"Head and Neck Cancer",
"Precancerous Condition"
] | [
"cetuximab",
"cisplatin",
"IMRT"
] | [
"BIOLOGICAL",
"DRUG",
"RADIATION"
] | [
"Overall Survival"
] | ALL | 18 Years | 120 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2011-06-01T00:00:00 | 2018-07-12T00:00:00 | 2025-09-04T00:00:00 | 2011-02-24T00:00:00 | 2026-07-20T00:00:00 | 185 | [
"United States",
"Canada"
] | true | https://clinicaltrials.gov/study/NCT01302834 | RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor gr... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT01340495 | Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy | Pilot Study of Proton Radiation Therapy for Invasive Breast Carcinoma Following Mastectomy | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | TREATMENT | NA | NONE | 70 | Massachusetts General Hospital | OTHER | Massachusetts General Hospital | [
"National Cancer Institute (NCI)"
] | [
"Invasive Breast Cancer"
] | [
"Proton Radiation"
] | [
"RADIATION"
] | [
"Number of Participants With Grade 3 or Higher Radiation Pneumonitis or Any Grade 4 Adverse Event"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2011-06-01T00:00:00 | 2017-04-01T00:00:00 | 2022-01-03T00:00:00 | 2011-04-22T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT01340495 | In this study we are looking at a type of radiation called proton radiation which is known to spare surrounding tissue and organs from radiation. The proton radiation will be delivered using 3D conformal proton radiation or scanned beam/IMPT (Intensity Modulated Proton Radiation Treatment). Proton radiation delivers no... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05504811 | FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease | FitMi AD: a Safe and Motivating Computer-guided Exercise System for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | TREATMENT | RANDOMIZED | SINGLE | 31 | Flint Rehabilitation Devices, LLC | INDUSTRY | Flint Rehabilitation Devices, LLC | [
"Rancho Research Institute, Inc."
] | [
"Cognitive Dysfunction",
"Dementia, Mild"
] | [
"FitMi AD",
"Conventional exercise program"
] | [
"DEVICE",
"OTHER"
] | [
"Change in Functional Reach Test",
"Change in Timed Up and Go Test",
"Change in 30 Second Chair Stand Test"
] | ALL | 50 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2023-09-08T00:00:00 | 2025-03-12T00:00:00 | 2025-03-12T00:00:00 | 2022-08-17T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT05504811 | This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. FitMi AD uses embedded sensors that can track and record the patient's direction and degree of movement while performing exercises de... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04489732 | MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer | Pilot Study of Mesenchymal Stromal Cells in Patients With Xerostomia After Radiation Therapy for Head and Neck Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE1"
] | TREATMENT | NA | NONE | 6 | University of Wisconsin, Madison | OTHER | University of Wisconsin, Madison | [
"National Institute of Dental and Craniofacial Research (NIDCR)"
] | [
"Xerostomia Following Radiotherapy"
] | [
"Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells"
] | [
"BIOLOGICAL"
] | [
"Percentage of Subjects Experiencing Dose Limiting Toxicity (DLT)"
] | ALL | 18 Years | 90 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2022-02-18T00:00:00 | 2022-11-22T00:00:00 | 2026-05-20T00:00:00 | 2020-07-28T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04489732 | This is a single center pilot study designed to determine the safety and tolerability of autologous bone marrow-derived Mesenchymal Stromal Cells (MSCs) in patients with xerostomia (dry mouth) after undergoing radiation therapy (XRT) for head and neck cancer (HNC). Up to 12 participants will be enrolled and can expect ... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04758780 | Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer | Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients | OPALESCENCE | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | DIAGNOSTIC | NA | NONE | 12 | Institut Cancerologie de l'Ouest | OTHER | Institut Cancerologie de l'Ouest | [
"Tarix Pharmaceuticals",
"SIRIC ILIAD"
] | [
"Triple Negative Breast Cancer"
] | [
"89Zr-TLX250"
] | [
"DRUG"
] | [
"Number of Total Lesions Detected on 89Zr-TLX250 PET/CT Versus 18FDG PET/CT",
"Number of Brain Lesions Seen on 89Zr-TLX250 PET/CT and on 18FDG PET/CT",
"Number of Breast Lesions Seen on 89Zr-TLX250 PET/CT and on 18FDG PET/CT",
"Number of Bone Lesions Seen on 89Zr-TLX250 PET/CT and on 18FDG PET/CT",
"Number ... | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-09-21T00:00:00 | 2023-03-31T00:00:00 | 2023-09-13T00:00:00 | 2021-02-17T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"France"
] | true | https://clinicaltrials.gov/study/NCT04758780 | The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05256888 | Time-Restricted Eating to Address Persistent Cancer-Related Fatigue | Time-Restricted Eating to Address Persistent Cancer-Related Fatigue: The Fatigue REDuction After Cancer (FREDA) Trial | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | SUPPORTIVE_CARE | RANDOMIZED | NONE | 50 | University of Maryland, Baltimore | OTHER | University of Maryland, Baltimore | [
"National Center for Advancing Translational Sciences (NCATS)"
] | [
"Neoplasms",
"Therapy",
"Fatigue",
"Diet Therapy",
"Time",
"Survivorship",
"Fasting, Intermittent"
] | [
"Time-restricted eating",
"Healthy lifestyle education"
] | [
"BEHAVIORAL"
] | [
"Feasibility, as Assessed by the Percentage of Participants Who Enrolled Completed the Study",
"Fatigue, as Assessed Using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Questionnaire"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2023-01-26T00:00:00 | 2024-06-01T00:00:00 | 2024-06-01T00:00:00 | 2022-02-25T00:00:00 | 2026-07-20T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT05256888 | This study will assess the feasibility of delivering a 12-week time-restricted eating intervention as well as the intervention's preliminary efficacy on persistent cancer-related fatigue among cancer survivors compared to a general health education control. Participants will be randomized 1:1 to one of two arms: time-r... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05120869 | Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention | Implementing Innovative and Strategic Approaches to Prevent and Mitigate the Deleterious Effects of HPV Across the Lifespan of Hispanics of Mexican Origin: Healthcare Provider Intervention | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | OTHER | RANDOMIZED | DOUBLE | 161 | University of Texas, El Paso | OTHER | University of Texas, El Paso | [
"National Institute on Minority Health and Health Disparities (NIMHD)",
"Burrell College of Health Sciences"
] | [
"Health Personnel Attitude",
"Health Knowledge, Attitudes, Practice"
] | [
"Tailored HPV Education and Professional Skills Intervention Group",
"General HPV Education and Communication Skills Control Group"
] | [
"BEHAVIORAL"
] | [
"Healthcare Provider (HCP) Practices Scale Score",
"Healthcare Provider (HCP) Practices Scale Score",
"Healthcare Provider (HCP) Practices Scale Score"
] | ALL | 18 Years | 65 Years | [
"ADULT",
"OLDER_ADULT"
] | true | 2023-12-22T00:00:00 | 2024-12-02T00:00:00 | 2024-12-02T00:00:00 | 2021-11-15T00:00:00 | 2026-07-20T00:00:00 | 2 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT05120869 | Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Our hypothesis is that improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesita... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression | null | COMPLETED | INTERVENTIONAL | [
"PHASE3"
] | TREATMENT | NA | NONE | 21 | Dartmouth-Hitchcock Medical Center | OTHER | Dartmouth-Hitchcock Medical Center | [] | [
"Acute Myeloid Leukemia",
"Chronic Lymphocytic Leukemia",
"Chronic Myeloid Leukemia",
"Myelodysplasia",
"Myeloproliferative Disorder",
"Myelofibrosis",
"Lymphoma",
"Lymphoma, Non-Hodgkin",
"Plasma Cell Disorder"
] | [
"Cyclophosphamide",
"Fludarabine",
"Total Body Irradiation",
"Tacrolimus",
"cellcept",
"g-csf",
"Peripheral Blood Transplant"
] | [
"DRUG",
"PROCEDURE",
"RADIATION"
] | [
"Number of Participants Who Survived to 100-Days Post-transplant",
"Number of Participants Who Survived to One Year Post-Transplant.",
"Number of Participants Who Experienced a Successful Engraftment",
"Number of Participants Who Achieved a Response to Treatment at 100 Days",
"Number of Participants Who Ach... | ALL | 18 Years | 75 Years | [
"ADULT",
"OLDER_ADULT"
] | true | 2018-03-28T00:00:00 | 2025-02-14T00:00:00 | 2025-10-17T00:00:00 | 2018-03-29T00:00:00 | 2026-07-17T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03480360 | The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 14 | Thomas Jefferson University | OTHER | Thomas Jefferson University | [
"Context Therapeutics Inc."
] | [
"Refractory Endometrial Adenocarcinoma",
"Refractory Endometrial Carcinoma",
"Refractory Endometrial Clear Cell Adenocarcinoma",
"Refractory Endometrial Endometrioid Adenocarcinoma",
"Refractory Endometrial Mixed Cell Adenocarcinoma",
"Refractory Endometrial Serous Adenocarcinoma",
"Refractory Endometri... | [
"Extended-release Onapristone",
"Anastrozole",
"Quality-of-Life Assessment",
"Questionnaire Administration",
"Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)",
"Progesterone Receptor Positive ( PGR Positive; PR Positive)"
... | [
"DIAGNOSTIC_TEST",
"DRUG",
"OTHER"
] | [
"Objective Response Rate (ORR)",
"Progression-Free Survival (PFS)"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2021-01-28T00:00:00 | 2025-03-01T00:00:00 | 2025-12-17T00:00:00 | 2021-01-22T00:00:00 | 2026-07-17T00:00:00 | 2 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04719273 | This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04542135 | Sulindac and Breast Density in Women at Risk of Developing Breast Cancer | Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | SINGLE | 61 | Alison Stopeck | OTHER | Stony Brook University | [
"Medical University of South Carolina",
"Cedars-Sinai Medical Center"
] | [
"Breast Cancer"
] | [
"Sulindac Pill",
"Placebo"
] | [
"DRUG"
] | [
"Change in Percent Breast Density by MRI Between Treatment Arms"
] | FEMALE | 35 Years | 70 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2020-11-20T00:00:00 | 2025-04-22T00:00:00 | 2025-05-19T00:00:00 | 2020-09-09T00:00:00 | 2026-07-17T00:00:00 | 2 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04542135 | The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects | Stereotactic Body Radiotherapy Radiotherapy With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects | STILE | COMPLETED | INTERVENTIONAL | [
"PHASE1",
"PHASE2"
] | TREATMENT | NA | NONE | 36 | Royal Marsden NHS Foundation Trust | OTHER | Royal Marsden NHS Foundation Trust | [
"Bristol-Myers Squibb"
] | [
"Non-small Cell Lung Cancer Stage II",
"Non-small Cell Lung Cancer Stage I"
] | [
"Stereotactic body radiotherapy",
"Nivolumab"
] | [
"DRUG",
"RADIATION"
] | [
"Assessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-02-08T00:00:00 | 2024-08-12T00:00:00 | 2025-06-26T00:00:00 | 2017-12-26T00:00:00 | 2026-07-17T00:00:00 | 1 | [
"United Kingdom"
] | true | https://clinicaltrials.gov/study/NCT03383302 | This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
SBRT will be delivered in either 3 or 5 fractions for peripheral disease or 8 fractions in central disease. A flat dose of 240 mg nivolumab infusion will beg... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT02071901 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | SUPPORTIVE_CARE | NA | NONE | 31 | Case Comprehensive Cancer Center | OTHER | Case Comprehensive Cancer Center | [] | [
"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome",
"Adult Acute Basophilic Leukemia",
"Adult Acute Eosinophilic Leukemia",
"Adult Acute Megakaryoblastic Leukemia (M7)",
"Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
"Adult Acute Monoblastic Leukemia (M5... | [
"eltrombopag olamine"
] | [
"DRUG"
] | [
"Number of Participants With a Median Platelet Count >= 50,000/uL"
] | ALL | 60 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2014-08-14T00:00:00 | 2018-10-20T00:00:00 | 2019-01-06T00:00:00 | 2014-02-26T00:00:00 | 2026-07-17T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT02071901 | This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complicat... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03314688 | Lifestyle, Exercise, and Nutrition Study Early After Diagnosis | Lifestyle, Exercise, and Nutrition Study Early After Diagnosis (LEANer) | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | OTHER | RANDOMIZED | DOUBLE | 173 | Yale University | OTHER | Yale University | [
"National Cancer Institute (NCI)"
] | [
"Breast Neoplasms"
] | [
"Dietary/Physical Activity intervention",
"Usual Care"
] | [
"BEHAVIORAL"
] | [
"Adherence to Treatment Measured by Chemotherapy Completion Rate",
"Adherence to Endocrine Therapy in Women Taking Tamoxifen or Aromatase Inhibitors (AIs)",
"Adherence to Endocrine Therapy in Women Taking Tamoxifen or Aromatase Inhibitors (AIs)."
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-01-02T00:00:00 | 2023-03-24T00:00:00 | 2023-06-20T00:00:00 | 2017-10-19T00:00:00 | 2026-07-17T00:00:00 | 2 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03314688 | The proposed study is a randomized trial evaluating the impact of a dietary and physical activity guidelines intervention vs. usual care on adherence to breast cancer treatments, body composition, and changes in biomarkers in 172 women newly diagnosed with breast cancer scheduled to receive neoadjuvant or adjuvant chem... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT04674306 | Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer | Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence | null | COMPLETED | INTERVENTIONAL | [
"EARLY_PHASE1"
] | TREATMENT | NON_RANDOMIZED | NONE | 35 | George T. Budd | OTHER | Case Comprehensive Cancer Center | [
"United States Department of Defense",
"Anixa Biosciences, Inc."
] | [
"Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer",
"TNBC - Triple-Negative Breast Cancer",
"Residual Disease"
] | [
"α-lactalbumin vaccine",
"Zymosan"
] | [
"BIOLOGICAL"
] | [
"Treatment Cohort MTD of α-lactalbumin Vaccine",
"Preventative Cohort MTD of α-lactalbumin Vaccine",
"Pembrolizumab Cohort of α-lactalbumin Vaccine"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | true | 2021-10-01T00:00:00 | 2025-12-15T00:00:00 | 2025-12-29T00:00:00 | 2020-12-19T00:00:00 | 2026-07-17T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT04674306 | The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer, participants who are of cancer-free but may be at risk for triple-negative breast cancer, and for part... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03938324 | Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions | Peer i-Coaching for Activated Self-management Optimization in Adolescents and Young Adults With Chronic Conditions | PiCASO | COMPLETED | INTERVENTIONAL | [
"NA"
] | SUPPORTIVE_CARE | RANDOMIZED | NONE | 222 | Duke University | OTHER | Duke University | [
"National Institutes of Health (NIH)",
"National Institute of Nursing Research (NINR)"
] | [
"Sickle Cell Disease",
"Chronic Kidney Diseases",
"Systemic Lupus Erythematosus",
"Childhood Cancer",
"Inflammatory Bowel Diseases",
"Stem Cell Transplant",
"Organ Transplant",
"Diabetes Mellitus, Type 1",
"Cystic Fibrosis"
] | [
"PiCASO Intervention Group",
"Sham Comparator: Attention Control Group"
] | [
"BEHAVIORAL"
] | [
"Change in Self-management as Measured by the Partners in Health Scale",
"Patient Activation as Measured by the Patient Activation Measure (PAM-13)"
] | ALL | 16 Years | 22 Years | [
"CHILD",
"ADULT"
] | false | 2019-10-29T00:00:00 | 2024-06-19T00:00:00 | 2024-06-19T00:00:00 | 2019-05-06T00:00:00 | 2026-07-17T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03938324 | The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood onset chronic conditions. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03716739 | Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | SUPPORTIVE_CARE | RANDOMIZED | DOUBLE | 136 | Dana-Farber Cancer Institute | OTHER | Dana-Farber Cancer Institute | [
"National Institute on Aging (NIA)"
] | [
"Prostate Cancer"
] | [
"Testosterone Cypionate 100 MG/ML",
"Placebo"
] | [
"DRUG"
] | [
"Number of Participants With Biochemical Recurrence of Prostate Cancer",
"Change From Baseline in Overall Sexual Activity, Assessed Using Psychosexual Diary Questionnaire (PDQ) Question 4"
] | MALE | 40 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-03-19T00:00:00 | 2025-05-16T00:00:00 | 2025-07-16T00:00:00 | 2018-10-23T00:00:00 | 2026-07-16T00:00:00 | 3 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03716739 | The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT07300202 | A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers | A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers | null | COMPLETED | INTERVENTIONAL | [
"PHASE1"
] | TREATMENT | NON_RANDOMIZED | NONE | 15 | Oriplantee Company Limited | OTHER | Oriplantee Company Limited | [
"Vietstar Biomedical Research"
] | [
"Breast Cancer"
] | [
"Orialpha (BD-C) at 0.25 x anticipated therapeutic dose",
"Orialpha (BD-C) at 0.5 x anticipated therapeutic dose",
"Orialpha (BD-C) at the anticipated therapeutic dose",
"Orialpha (BD-C) at 1.5 x anticipated therapeutic dose",
"Orialpha (BD-C) at 2 x anticipated therapeutic dose"
] | [
"DRUG"
] | [
"Absolute Number of Subjects Experiencing Treatment-related Adverse Events in Each Cohort",
"Absolute Number of Subjects Experiencing Adverse Events Leading to Study Discontinuation in Each Cohort",
"Absolute Number of Subjects Experiencing Serious Adverse Events (SAEs) in Each Cohort"
] | ALL | 18 Years | 60 Years | [
"ADULT"
] | true | 2025-02-13T00:00:00 | 2025-06-16T00:00:00 | 2025-08-31T00:00:00 | 2025-12-23T00:00:00 | 2026-07-16T00:00:00 | 1 | [
"Vietnam"
] | true | https://clinicaltrials.gov/study/NCT07300202 | This Phase I clinical study is designed to evaluate the safety and determine the maximum tolerated dose (MTD) of Orialpha (BD-C) in healthy adult volunteers. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer | ANCHOR-CRC | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 95 | Pierre Fabre Medicament | INDUSTRY | Pierre Fabre Medicament | [
"Pfizer",
"Merck KGaA, Darmstadt, Germany"
] | [
"BRAF V600E-mutant Metastatic Colorectal Cancer"
] | [
"encorafenib",
"Binimetinib",
"Cetuximab"
] | [
"DRUG"
] | [
"Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2019-01-17T00:00:00 | 2020-06-29T00:00:00 | 2023-04-27T00:00:00 | 2018-10-02T00:00:00 | 2026-07-16T00:00:00 | 45 | [
"United States",
"Austria",
"Belgium",
"France",
"Italy",
"Japan",
"Netherlands",
"Spain",
"United Kingdom"
] | true | https://clinicaltrials.gov/study/NCT03693170 | The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT03405155 | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | Phase II Study of Adjuvant Nivolumab in Patients With Resected Stage IIB/IIC Melanoma | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | NA | NONE | 26 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | OTHER | Thomas Jefferson University | [
"Bristol-Myers Squibb"
] | [
"Melanoma (Skin)"
] | [
"Nivolumab"
] | [
"BIOLOGICAL"
] | [
"Recurrence-free Survival"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2018-01-17T00:00:00 | 2025-12-15T00:00:00 | 2025-12-15T00:00:00 | 2018-01-19T00:00:00 | 2026-07-16T00:00:00 | 4 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT03405155 | This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment | null | COMPLETED | INTERVENTIONAL | [
"PHASE4"
] | TREATMENT | NA | NONE | 34 | Novartis Pharmaceuticals | INDUSTRY | Novartis | [] | [
"Gastrointestinal Stromal Tumors"
] | [
"Nilotinib"
] | [
"DRUG"
] | [
"Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0."
] | ALL | 18 Years | 100 Years | [
"ADULT",
"OLDER_ADULT"
] | false | 2008-08-29T00:00:00 | 2024-12-18T00:00:00 | 2024-12-18T00:00:00 | 2008-09-22T00:00:00 | 2026-07-16T00:00:00 | 10 | [
"Finland",
"France",
"Germany",
"Italy",
"Spain"
] | true | https://clinicaltrials.gov/study/NCT00756509 | The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT06415656 | VitalTraq for the Detection of CRS | Digital Multi-Vital Sign Monitoring for Early Detection of Cytokine Release Syndrome From Bispecific T-Cell Engagers and Chimeric Antigen Receptor Therapy | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | DIAGNOSTIC | NA | NONE | 32 | Duke University | OTHER | Duke University | [
"Blue Spark Technologies"
] | [
"Hematologic Malignancy"
] | [
"TempTraq",
"VitalTraq"
] | [
"DEVICE"
] | [
"TempTraq's Ability to Measure Axillary Temperature in the Intended Use Population"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2024-10-13T00:00:00 | 2025-06-15T00:00:00 | 2025-07-07T00:00:00 | 2024-05-16T00:00:00 | 2026-07-15T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT06415656 | The purpose of this study is to evaluate two vital sign monitoring devices, TempTraq and VitalTraq, in patients with hematologic malignancies undergoing therapy with Chimeric antigen receptor T-cell therapy (CAR-T) or Bispecific T-cell engagers (BiTE) products. TempTraq is an axillary patch that is worn on the skin and... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT06465368 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING | null | COMPLETED | INTERVENTIONAL | [
"PHASE2"
] | TREATMENT | RANDOMIZED | NONE | 121 | Pfizer | INDUSTRY | Pfizer | [] | [
"Breast Cancer"
] | [
"PF-07220060",
"letrozole"
] | [
"DRUG"
] | [
"Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14"
] | FEMALE | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2024-07-11T00:00:00 | 2025-07-10T00:00:00 | 2025-07-10T00:00:00 | 2024-06-18T00:00:00 | 2026-07-15T00:00:00 | 51 | [
"United States",
"Australia",
"Belgium",
"France",
"Germany",
"Italy",
"Poland",
"Slovakia",
"South Korea",
"Spain",
"Sweden",
"Switzerland",
"Taiwan"
] | true | https://clinicaltrials.gov/study/NCT06465368 | The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer.
This study is seeking for participants who are:
* women of age 18 years and older post menopause (either nat... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05594043 | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | null | COMPLETED | INTERVENTIONAL | [
"PHASE1"
] | TREATMENT | NON_RANDOMIZED | NONE | 39 | Merck Sharp & Dohme LLC | INDUSTRY | Merck Sharp & Dohme LLC | [] | [
"Advanced or Metastatic Solid Tumors"
] | [
"MK-6598",
"Pembrolizumab"
] | [
"BIOLOGICAL",
"DRUG"
] | [
"Number of Participants With a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 5.0",
"Number of Participants Who Experienced At Least One AE",
"Number of Participants Who Discontinue Study Treatment Due to an AE"
] | ALL | 18 Years | null | [
"ADULT",
"OLDER_ADULT"
] | false | 2022-12-21T00:00:00 | 2025-05-21T00:00:00 | 2025-05-21T00:00:00 | 2022-10-26T00:00:00 | 2026-07-15T00:00:00 | 6 | [
"United States",
"Canada",
"Switzerland"
] | true | https://clinicaltrials.gov/study/NCT05594043 | The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors. | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
NCT05453630 | Colonoscopy Outreach for Rural Communities Aim 2 | Colonoscopy Outreach for Rural Communities Aim 2 | null | COMPLETED | INTERVENTIONAL | [
"NA"
] | HEALTH_SERVICES_RESEARCH | RANDOMIZED | DOUBLE | 527 | University of Washington | OTHER | University of Washington | [
"National Cancer Institute (NCI)"
] | [
"Colorectal Cancer"
] | [
"Patient Navigation",
"Usual Care Control"
] | [
"BEHAVIORAL"
] | [
"Number of Participants Who Complete Colonoscopy Within 1 Year of the Colonoscopy Referral"
] | ALL | 45 Years | 915 Months | [
"ADULT",
"OLDER_ADULT"
] | true | 2022-06-16T00:00:00 | 2025-07-15T00:00:00 | 2025-07-15T00:00:00 | 2022-07-12T00:00:00 | 2026-07-15T00:00:00 | 1 | [
"United States"
] | true | https://clinicaltrials.gov/study/NCT05453630 | This study aims to test the effectiveness of a remotely-delivered patient navigation program for increasing colonoscopy completion for colorectal cancer screening, among rural populations. The study will partner with geographically disparate primary care organizations to recruit patients aged 45-75 to the study. The pa... | 2026-08-03T01:30:13 | condition=cancer | SNlgGFlFSLbGtam7G | zdaHCUf74XDUOdGwP |
End of preview.
ClinicalTrials Scraper
Scrape ClinicalTrials.gov studies by condition, intervention, sponsor, phase, status or country. Returns one row per NCT trial with sponsors, phases, enrolment, outcomes and locations. No API key.
| Rows in this dataset | 11,191 |
| Fields | 63 |
| Collector runs behind it | 65 |
| Most recent observation | 2026-08-03 |
| Browsable presentation | https://reapx.dev/data/clinicaltrials-scraper/ — 8,112 entity pages |
| Run the collector yourself | https://apify.com/reapx/clinicaltrials-scraper |
What this is
Every row here was returned by a real run of a public collector. Nothing is generated from a template over a keyword list: a row exists because a run observed it.
A browsable presentation of the subset that carries an addressable nctId is published as
8,112 entity pages at https://reapx.dev/data/clinicaltrials-scraper/, one page per entity. This dataset is
the larger of the two — rows whose payload has no field that can address a page are here and
are not published there.
Provenance
Each row carries _run_id and _dataset_id, naming the collector run that produced it, so any
row can be traced back to the run that observed it. Rows observed by more than one run are
deduplicated on content; 0 duplicate observations were collapsed.
Files
clinicaltrials-scraper.jsonl— one JSON object per row, the canonical formclinicaltrials-scraper.csv— the same rows flattened; nested values are JSON-encoded within their cell so they round-tripdataset.json— schema.orgDatasetmetadata
Loading it
from datasets import load_dataset
ds = load_dataset("reapxdev/clinicaltrials-scraper", split="train")
A sample of the published entities
- NCT00001184
- NCT03312465
- NCT04539366
- NCT05239364
- NCT05761561
- NCT06176690
- NCT06568939
- NCT06902896
- NCT07137338
- NCT07332481
- NCT07552779
- NCT07682532
Related
- All sources: https://reapx.dev/data/ · machine-readable index: https://reapx.dev/llms.txt
- The collector is a public Apify Actor; agents reach it through https://mcp.apify.com
Licence
Collected from public sources. This metadata and the published pages are CC BY 4.0; the underlying records remain under the terms of their originating source.
- Downloads last month
- 10